Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Update

Vincerx Pharma, Inc. (NASDAQ:VINC) was the recipient of a large decrease in short interest during the month of May. As of May 31st, there was short interest totalling 1,000 shares, a decrease of 50.0% from the May 15th total of 2,000 shares. Based on an average daily volume of 185,900 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.1% of the shares of the company are sold short.

Vincerx Pharma Stock Down 9.1%

NASDAQ VINC traded down $0.01 during midday trading on Monday, hitting $0.05. The company had a trading volume of 27,475 shares, compared to its average volume of 433,518. The firm has a fifty day simple moving average of $0.10 and a two-hundred day simple moving average of $1.56. Vincerx Pharma has a fifty-two week low of $0.04 and a fifty-two week high of $17.17. The stock has a market cap of $261,700.00, a price-to-earnings ratio of 0.00 and a beta of 1.75.

About Vincerx Pharma

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.